In a clinical trial (I-SPY TRIAL, NCT01277757), MK-2206 is currently tested in combination with or without trastuzumab for treatment of advanced breast cancer with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation [115]. This evidence concerns the gene PIK3CA and breast cancer.